Loading
A phase 3 trial of Belzutifan, Nivolumab, Lenvatinib and Cabozantinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) is a phase 3 interventional study registered as NCT07405164 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2026-03-23 and due to reach its primary completion in 2034-01-14. Interventions recorded: Belzutifan, Nivolumab, Lenvatinib and Cabozantinib.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.